Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat

G. Cavaletti, G. Tredici, M. G. Petruccioli, E. Dondè, P. Tredici, P. Marmiroli, C. Minoia, A. Ronchi, M. Bayssas, G. Griffon Etienne

Research output: Contribution to journalArticle

194 Citations (Scopus)

Abstract

The aim of this study was to determine the influence of oxaliplatin scheduling on the onset of peripheral neurotoxicity and ototoxicity in a rat model. Animals were treated with four different schedules of oxaliplatin using two cumulative doses (36 and 48 mg/kg intraperitoneally (i.p.)). The neuropathological examination evidenced dorsal root ganglia (DRG) nucleolar, nuclear and somatic size reduction with nucleolar segregation in the treated rats. Sensory nerve conduction velocity (SNCV) was reduced after oxaliplatin treatment, while the auditory pathway was unaffected. After treatment, platinum was detected in the kidney, DRG and sciatic nerve. After a 5-week follow-up period, recovery of the pathological changes in the DRG and sciatic nerves occurred, although platinum was still detectable in these tissues. The following conclusions may be drawn: the main targets of oxaliplatin neurotoxicity were the DRG; the shorter the interval between the injections, the higher the severity of peripheral neuropathy and this was also related to the cumulative oxaliplatin dose; the peripheral neurotoxicity tended to be reversible; ototoxicity was absent even with high cumulative doses of oxaliplatin.

Original languageEnglish
Pages (from-to)2457-2463
Number of pages7
JournalEuropean Journal of Cancer
Volume37
Issue number18
DOIs
Publication statusPublished - 2001

Fingerprint

oxaliplatin
Peripheral Nervous System
Appointments and Schedules
Spinal Ganglia
Sciatic Nerve
Platinum
Therapeutics
Auditory Pathways
Neural Conduction
Peripheral Nervous System Diseases

Keywords

  • Audiometry
  • Neuropathy
  • Oxaliplatin
  • Rat
  • Toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Cavaletti, G., Tredici, G., Petruccioli, M. G., Dondè, E., Tredici, P., Marmiroli, P., ... Griffon Etienne, G. (2001). Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. European Journal of Cancer, 37(18), 2457-2463. https://doi.org/10.1016/S0959-8049(01)00300-8

Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. / Cavaletti, G.; Tredici, G.; Petruccioli, M. G.; Dondè, E.; Tredici, P.; Marmiroli, P.; Minoia, C.; Ronchi, A.; Bayssas, M.; Griffon Etienne, G.

In: European Journal of Cancer, Vol. 37, No. 18, 2001, p. 2457-2463.

Research output: Contribution to journalArticle

Cavaletti, G, Tredici, G, Petruccioli, MG, Dondè, E, Tredici, P, Marmiroli, P, Minoia, C, Ronchi, A, Bayssas, M & Griffon Etienne, G 2001, 'Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat', European Journal of Cancer, vol. 37, no. 18, pp. 2457-2463. https://doi.org/10.1016/S0959-8049(01)00300-8
Cavaletti, G. ; Tredici, G. ; Petruccioli, M. G. ; Dondè, E. ; Tredici, P. ; Marmiroli, P. ; Minoia, C. ; Ronchi, A. ; Bayssas, M. ; Griffon Etienne, G. / Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. In: European Journal of Cancer. 2001 ; Vol. 37, No. 18. pp. 2457-2463.
@article{64de5dc2040d4375838e628047c94932,
title = "Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat",
abstract = "The aim of this study was to determine the influence of oxaliplatin scheduling on the onset of peripheral neurotoxicity and ototoxicity in a rat model. Animals were treated with four different schedules of oxaliplatin using two cumulative doses (36 and 48 mg/kg intraperitoneally (i.p.)). The neuropathological examination evidenced dorsal root ganglia (DRG) nucleolar, nuclear and somatic size reduction with nucleolar segregation in the treated rats. Sensory nerve conduction velocity (SNCV) was reduced after oxaliplatin treatment, while the auditory pathway was unaffected. After treatment, platinum was detected in the kidney, DRG and sciatic nerve. After a 5-week follow-up period, recovery of the pathological changes in the DRG and sciatic nerves occurred, although platinum was still detectable in these tissues. The following conclusions may be drawn: the main targets of oxaliplatin neurotoxicity were the DRG; the shorter the interval between the injections, the higher the severity of peripheral neuropathy and this was also related to the cumulative oxaliplatin dose; the peripheral neurotoxicity tended to be reversible; ototoxicity was absent even with high cumulative doses of oxaliplatin.",
keywords = "Audiometry, Neuropathy, Oxaliplatin, Rat, Toxicity",
author = "G. Cavaletti and G. Tredici and Petruccioli, {M. G.} and E. Dond{\`e} and P. Tredici and P. Marmiroli and C. Minoia and A. Ronchi and M. Bayssas and {Griffon Etienne}, G.",
year = "2001",
doi = "10.1016/S0959-8049(01)00300-8",
language = "English",
volume = "37",
pages = "2457--2463",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "18",

}

TY - JOUR

T1 - Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat

AU - Cavaletti, G.

AU - Tredici, G.

AU - Petruccioli, M. G.

AU - Dondè, E.

AU - Tredici, P.

AU - Marmiroli, P.

AU - Minoia, C.

AU - Ronchi, A.

AU - Bayssas, M.

AU - Griffon Etienne, G.

PY - 2001

Y1 - 2001

N2 - The aim of this study was to determine the influence of oxaliplatin scheduling on the onset of peripheral neurotoxicity and ototoxicity in a rat model. Animals were treated with four different schedules of oxaliplatin using two cumulative doses (36 and 48 mg/kg intraperitoneally (i.p.)). The neuropathological examination evidenced dorsal root ganglia (DRG) nucleolar, nuclear and somatic size reduction with nucleolar segregation in the treated rats. Sensory nerve conduction velocity (SNCV) was reduced after oxaliplatin treatment, while the auditory pathway was unaffected. After treatment, platinum was detected in the kidney, DRG and sciatic nerve. After a 5-week follow-up period, recovery of the pathological changes in the DRG and sciatic nerves occurred, although platinum was still detectable in these tissues. The following conclusions may be drawn: the main targets of oxaliplatin neurotoxicity were the DRG; the shorter the interval between the injections, the higher the severity of peripheral neuropathy and this was also related to the cumulative oxaliplatin dose; the peripheral neurotoxicity tended to be reversible; ototoxicity was absent even with high cumulative doses of oxaliplatin.

AB - The aim of this study was to determine the influence of oxaliplatin scheduling on the onset of peripheral neurotoxicity and ototoxicity in a rat model. Animals were treated with four different schedules of oxaliplatin using two cumulative doses (36 and 48 mg/kg intraperitoneally (i.p.)). The neuropathological examination evidenced dorsal root ganglia (DRG) nucleolar, nuclear and somatic size reduction with nucleolar segregation in the treated rats. Sensory nerve conduction velocity (SNCV) was reduced after oxaliplatin treatment, while the auditory pathway was unaffected. After treatment, platinum was detected in the kidney, DRG and sciatic nerve. After a 5-week follow-up period, recovery of the pathological changes in the DRG and sciatic nerves occurred, although platinum was still detectable in these tissues. The following conclusions may be drawn: the main targets of oxaliplatin neurotoxicity were the DRG; the shorter the interval between the injections, the higher the severity of peripheral neuropathy and this was also related to the cumulative oxaliplatin dose; the peripheral neurotoxicity tended to be reversible; ototoxicity was absent even with high cumulative doses of oxaliplatin.

KW - Audiometry

KW - Neuropathy

KW - Oxaliplatin

KW - Rat

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=0035196664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035196664&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(01)00300-8

DO - 10.1016/S0959-8049(01)00300-8

M3 - Article

C2 - 11720843

AN - SCOPUS:0035196664

VL - 37

SP - 2457

EP - 2463

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 18

ER -